
Please try another search
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the...
Patent publication in Europe strengthens Clearmind's global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (GLOBE NEWSWIRE) --...
VANCOUVER - Clearmind Medicine Inc. (NASDAQ:CMND), a clinical-stage biotech company with a market capitalization of $5.03 million, has announced the filing of a new international...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Buy | Buy | Strong Sell |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bullish | 30 | Current | |||
Harami Cross | 1M | Current |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Sasol | 7,300 | 7,367 | 6,769 | +392 | +5.67% | 4.17M | 19/05 | ||
Aspen Pharmacare | 11,914 | 12,217 | 11,768 | -287 | -2.35% | 1.31M | 19/05 | ||
RENERGEN | 700 | 737 | 551 | -38 | -5.15% | 1.19M | 19/05 | ||
Blue Label | 1,000 | 1,026 | 988 | +10 | +1.01% | 1.75M | 19/05 | ||
Sibanye Stillwater | 2,192 | 2,235 | 2,133 | +56 | +2.62% | 19.85M | 19/05 | ||
Capitec | 348,981 | 351,980 | 342,303 | -1237 | -0.35% | 231.54K | 19/05 | ||
Naspers | 527,000 | 532,321 | 520,692 | -6226 | -1.17% | 410.84K | 19/05 | ||
Thungela Resources | 8,735.00 | 8,744.00 | 8,423.00 | +280.00 | +3.31% | 313.59K | |||
Pick n Pay | 2,650 | 2,678 | 2,627 | -2 | -0.08% | 1.29M | 19/05 | ||
Valterra Platinum | 61,798 | 63,000 | 61,001 | +725 | +1.19% | 392.23K | 19/05 |
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is based in Vancouver, Canada.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review